Publications for Johan Rosell
Co-author map based on ISI articles 2007-
Publications mentioned in social media 24 times*
Journal Articles
Hans Olsson, Peter Söderkvist, Per Hultman, Johan Rosell and Staffan Jahnson
MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1
BMC Urology, 2013, 13(5), .
Fulltext  |
Johan Rosell, Bo Nordenskjöld, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per-Olof Malmstrom, Arne Wallgren, Olle Stål and John Carstensen
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
Breast Cancer Research and Treatment, 2013, 138(2), 467-473.
|
Annika Malmström, Roger Stupp, Monika Hegi, Johan Rosell and Roger Henriksson
Treatment options in elderly patients with glioblastoma - Authors' reply
The Lancet Oncology, 2012, 13(11), E461-E462.
|
Georg Jancke, Johan Rosell and Staffan Jahnson
Residual tumour in the marginal resection after a complete transurethral resection is associated with local recurrence in Ta/T1 urinary bladder cancer
Scandinavian Journal of Urology and Nephrology, 2012, 46(5), 343-347.
|
Hans Olsson, Per Hultman, Nastaran Monsef, Johan Rosell and Staffan Johanson
Immunohistochemical Evaluation of Cell Cycle Regulators: Impact on Predicting Prognosis in Stage T1 Urinary Bladder Cancer
ISRN Urology, 2012, 2012, .
|
Hans Olsson, Per Hultman, Johan Rosell and Staffan Jahnson
Population-based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumours
Scandinavian Journal of Urology and Nephrology, 2012, , .
|
Annika Malmström, Bjorn Henning Gronberg, Christine Marosi, Roger Stupp, Didier Frappaz, Henrik Schultz, Ufuk Abacioglu, Bjorn Tavelin, Benoit Lhermitte, Monika E Hegi, Johan Rosell and Roger Henriksson
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
The Lancet Oncology, 2012, 13(9), 916-926.
Web of Science® Times Cited: 11 |
Georg Jancke, Johan Rosell, Gunilla Chebil and Staffan Jahnson
Bladder Wash Cytology at Diagnosis of Ta-T1 Bladder Cancer Is Predictive for Recurrence and Progression
Urology, 2012, 80(3), 625-631.
|
Yang-mei Shen, Gunnar Arbman, Per Sandström, Per Gullstrand, Yu-Quan Wei, Hong Zhang, Johan Rosell, Birgit Olsson, Feng Peng, Han-Shuo Yang, Chun-Ting Wang and Xiao-Feng Sun
Novel gene hBiot2 is an independent prognostic factor in colorectal cancer patients
Oncology Reports, 2012, 27(2), 376-382.
|
Georg Jancke, Johan Rosell and Staffan Jahnson
Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder
Scandinavian Journal of Urology and Nephrology, 2011, 45(6), 388-392.
Web of Science® Times Cited: 2 |
Laszlo Tabar, Bedrich Vitak, Tony Hsiu-Hsi Chen, Amy Ming-Fang Yen, Anders Cohen, Tibor Tot, Sherry Yueh-Hsia Chiu, Sam Li-Sheng Chen, Jean Ching-Yuan Fann, Johan Rosell, Helena Fohlin, Robert A Smith and Stephen W Duffy
Swedish Two-County Trial: Impact of Mammographic Screening on Breast Cancer Mortality during 3 Decades
Radiology, 2011, 260(3), 658-663.
Web of Science® Times Cited: 43 |
Gabriel Sandblom, Eberhard Varenhorst, Johan Rosell, Owe Lofman and Per Carlsson
Letter: PROSTATE CANCER SCREENING Authors reply
BMJ. British Medical Journal, 2011, 342, .
|
Gabriel Sandblom, Eberhard Varenhorst, Johan Rosell, Owe Lofman and Per Carlsson
Randomised prostate cancer screening trial: 20 year follow-up
BRITISH MEDICAL JOURNAL, 2011, 342(d1539), .
Fulltext Web of Science® Times Cited: 29 |
Jasmine Loof, Johan Rosell, Charlotte Bratthall, Siv Doré, Hans Starkhammar, Hong Zhang and Xiao-Feng Sun
Impact of PINCH expression on survival in colorectal cancer patients
BMC CANCER, 2011, 11(103), .
Fulltext Web of Science® Times Cited: 1 |
Johan Rosell, Bo Nordenskjöld, N-O Bengtsson, T Fornander, T Hatschek, H Lindman, P-O Malmstrom, A Wallgren, Olle Stål and John Carstensen
Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
BRITISH JOURNAL OF CANCER, 2011, 104(6), 899-902.
Web of Science® Times Cited: 2 |
Staffan Jahnson, Ole Damm, Sverker Hellsten, Sten Holmang, Fredrik Liedberg, Borje Ljungberg, Per-Uno Malmstrom, Wiking Mansson, Johan Rosell and Hans Wijkstom
Urinary diversion after cystectomy for bladder cancer: A population-based study in Sweden
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2010, 44(2), 69-75.
Web of Science® Times Cited: 3 |
Katja Fall, Fredrik Strömberg, Johan Rosell and Eberhard Varenhorst
Reliability of death certificates in prostate cancer patients
Scandinavian Journal of Urology and Nephrology, 2008, 42(4), 352-357.
|
Jingfang Gao, Gunnar Arbman, L.. He, Zhiyong Zhang, Z. Zhao, Johan Rosell and Xiao-Feng Sun
MANBA polymorphism was related to increased risk of colorectal cancer in Swedish but not in Chinese populations
Acta Oncologica, 2008, 47(3), 372-378.
|
Georg Jancke, Ole Damm, Johan Rosell and Staffan Jahnson
Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer
Scandinavian Journal of Urology and Nephrology, 2008, 42(5), 417-421.
|
David Robinson, Gunnar Aus, Julia Bak, Tomasz Gorecki, Anders Herder, Johan Rosell and Eberhard Varenhorst
Long-term follow-up of conservatively managed incidental carcinoma of the prostate A multivariate analysis of prognostic factors
Scandinavian Journal of Urology and Nephrology, 2007, 41(2), 103-109.
Web of Science® Times Cited: 13 |
Gunnar Aus, David Robinson, Johan Rosell, Gabriel Sandblom and Eberhard Varenhorst
Survival in prostate carcinoma - Outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: Results from three counties in the population-based National Prostate Cancer Registry of Sweden
Cancer, 2005, 103(5), 943- 951.
Web of Science® Times Cited: 30 |
Bo Nordenskjöld, Johan Rosell, Lars-Erik Rutqvist, Per-Olof Malmström, Jonas Bergh, Nils-Olof Bengtsson, Thomas Hatschek, Arne Wallgren and John Carstensen
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial
Journal of the National Cancer Institute, 2005, 97(21), 1609-1610.
Web of Science® Times Cited: 34 |
Gabriel Sandblom, Eberhard Varenhorst, Owe Löfman, Johan Rosell and Per Carlsson
Clinical consequences of screening for prostate cancer: 15 Years follow-up of a randomised controlled trial in Sweden
European Urology, 2004, 46(6), 717-723.
Web of Science® Times Cited: 42 |
Gunnar Aus, Kerstin Nordenskjöld, David Robinson, Johan Rosell and Eberhard Varenhorst
Prognostic Factors and Survival in Node-Positive (N1) Prostate Cancer: A Prospective Study Based on Data from a Swedish Population-Based Cohort
European Urology, 2003, 43(6), 627-631.
Web of Science® Times Cited: 14 |
* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.
Ph.D., Lic. Theses
